The two rivals are approved for insomnia in the US but not in Europe, giving Idorsia first-mover advantage and a chance to make a breakthrough in the region. The Swiss company reckons Quviviq is ...

an indicator of the financial potential of the drug and its importance to Idorsia's growth. Quviviq (daridorexant) for insomnia contributed CHF 6.5 million, with the remainder coming from contract ...

Quviviq (daridorexant) can cause side effects that range from mild to serious. More common side effects include excessive sleepiness. If side effects from Quviviq become difficult to tolerate ...

As with other drugs, Quviviq (daridorexant) can cause side effects, such as sleep paralysis and hallucinations. If you are not able to tolerate side effects of Quviviq, talk with your doctor or ...

The company has defined the following strategic priorities that would drive decision-making at Idorsia: Unlocking the value of QUVIVIQ We must overcome the barriers to prescription wherever we ...

As of today, the company no longer expects to reach an agreement with the undisclosed party, allowing Idorsia to pivot to potential alternative parties at the end of the exclusivity period – end ...

The partnership between the US military body and the non-profit Global Coalition for Adaptive Research will examine three drugs as potential therapies.

About the agreement with Nxera for daridorexant In 2023, Idorsia out-licensed daridorexant to Nxera Pharma in the Asia-Pacific region (excluding China). QUVIVIQ™ (daridorexant) was approved for the ...

The company has defined the following strategic priorities that would drive decision-making at Idorsia: Unlocking the value of QUVIVIQ We must overcome the barriers to prescription wherever we find ...

Ad hoc announcement pursuant to Art. 53 LR The updated invitation to the bondholder meeting – scheduled for February 25, 2025 – sets out the ...